Analysed OUTLOOK THERAPEUTICS INC (OTLK:NASDAQ) News Sources
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
01-10-2026
yahoo.com
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
06-10-2026
yahoo.com
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
12-08-2026
yahoo.com
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
14-08-2026
yahoo.com
Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet
15-08-2026
yahoo.com
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
27-08-2026
yahoo.com
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
11-09-2026
yahoo.com
What is the current price of OUTLOOK THERAPEUTICS INC (OTLK:NASDAQ)?
The current price of OUTLOOK THERAPEUTICS INC (OTLK:NASDAQ) is $0.4882.
OUTLOOK THERAPEUTICS INC (OTLK:NASDAQ) absolute price change since previous trading day?
The absolute price change of OUTLOOK THERAPEUTICS INC (OTLK:NASDAQ) since the previous trading day is $-0.0118.
OUTLOOK THERAPEUTICS INC (OTLK:NASDAQ) percentage price change since previous trading day?
The percentage price change of OUTLOOK THERAPEUTICS INC (OTLK:NASDAQ) since the previous trading day is -2.36%.
What is the most recent average sentiment score for OUTLOOK THERAPEUTICS INC (OTLK:NASDAQ)?
The most recent average sentiment score for OUTLOOK THERAPEUTICS INC (OTLK:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for OUTLOOK THERAPEUTICS INC (OTLK:NASDAQ)?
The most recent sentiment for OUTLOOK THERAPEUTICS INC (OTLK:NASDAQ) is .
SEC-8K** Filing Available For OUTLOOK THERAPEUTICS INC (OTLK:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.